SCHEMBL185365

SCHEMBL185365

CC(C)(C)OC(=O)NCc1cccc(CNCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.55
GLS O94925 3/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA7 P43166 1/20 0.53
CA14 Q9ULX7 1/20 0.53
HDAC1 Q13547 1/20 0.51
NAMPT P43490 2/20 0.50
KDM4A O75164 1/20 0.50
CTSK P43235 1/20 0.49
IDO1 P14902 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
ALOX12 P18054 1/20 0.47
BRD4 O60885 1/20 0.47
RIPK1 Q13546 1/20 0.47
SYK P43405 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184991 0.94 HDAC1 (0.60) ATMGLSCA12CA1CA7
SCHEMBL3838871 0.89 CA12 (0.63) ATMCA12CA1CA7CA14
SCHEMBL15163979 0.89 GRM2 (0.52) ATMGLSHDAC1NAMPTCTSK
SCHEMBL185129 0.87 GLS (0.47) GLSHDAC1NAMPTL3MBTL1
Acetaldehyde SCHEMBL3344850 0.87 CA12 (0.57) ATMCA12CA1CA7CA14
Acetic Acid SCHEMBL7982271 0.86 CA12 (0.60) ATMCA12CA1CA7CA14
SCHEMBL13315979 0.86 GLS (0.52) GLSCA12CA1CA7CA14
SCHEMBL2735030 0.86 GRM2 (0.54) ATMGLSHDAC1NAMPTALDH1A1
SCHEMBL694491 0.86 GLS (0.56) ATMGLSCA12CA1CA7
SCHEMBL2787151 0.86 GLS (0.58) GLSCA12CA1CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
EP-2297103-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS Bristol-Myers Squibb Company (US) 2011-03-23 EP disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 ATM 4129/4885GLS 188/4885CA12 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.